Ardsley Advisory Partners’s Acer Therapeutics Inc ACER Stock Holding History

Ardsley Advisory Partners’s Portfolio ACER Stock Details ACER Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-18,000	Closed	-$437K	–	184
2019 Q1	$437K	Sell	18,000 -2,000	-10%	-$47.2K	0.08%	86
2018 Q4	$402K	Hold	20,000	–	–	0.1%	75
2018 Q3	$617K	Hold	20,000	–	–	0.08%	92
2018 Q2	$432K	Hold	20,000	–	–	0.07%	119
2018 Q1	$386K	Buy	20,000 +4,700	+31%	+$86.1K	0.06%	110
2017 Q4	$212K	Buy	+15,300	New	+$249K	0.03%	124

Other funds holding ACER

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Ardsley Advisory Partners's ACER Position: Q2 2019 in Review

Ardsley Advisory Partners sold out of Acer Therapeutics Inc (ACER) in Q2 2019, closing a stake of 18,000 shares — an estimated $437K sold.

Ardsley Advisory Partners first reported a position in ACER in Q4 2017 and held it in 6 quarters. The position peaked at $617K in Q3 2018. 37 funds tracked by Wall St. Rank hold ACER as of Q2 2019.

Ardsley Advisory Partners reported no remaining Acer Therapeutics Inc position as of Q2 2019 after selling out during the quarter.
Ardsley Advisory Partners sold 18,000 Acer Therapeutics Inc shares in Q2 2019, an estimated $437K.
Ardsley Advisory Partners first reported a position in Acer Therapeutics Inc in Q4 2017 and held it in 6 quarters.
Ardsley Advisory Partners's Acer Therapeutics Inc position peaked at $617K in Q3 2018.
37 funds tracked by Wall St. Rank held Acer Therapeutics Inc as of Q2 2019.

Based on Ardsley Advisory Partners's 13F filing for Q2 2019, filed 13 Aug 2019.